$SVRA
Savara Inc

2017 Form 10-K Financial Statement

#000156459018005610 Filed on March 14, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016 Q3
Revenue $0.00 $400.0K $45.00K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.880M $1.930M $1.000M
YoY Change -4.95% -23.41% -59.35%
% of Gross Profit
Research & Development $18.51M $80.00K $2.142M
YoY Change 126.25% -98.88% -70.78%
% of Gross Profit
Depreciation & Amortization $363.0K -$160.0K $86.00K
YoY Change 4.91% -500.0% 115.0%
% of Gross Profit
Operating Expenses $29.96M $2.030M $3.230M
YoY Change 163.98% -79.09% -67.01%
Operating Profit -$29.96M -$4.044M -$3.230M
YoY Change 173.62% -58.37% -67.13%
Interest Expense $1.161M -$140.0K $0.00
YoY Change 156.86% -70.21% -100.0%
% of Operating Profit
Other Income/Expense, Net -$3.475M -$10.00K $3.000K
YoY Change 946.69% -150.0% -120.0%
Pretax Income -$33.43M -$8.440M -$3.227M
YoY Change 196.37% -16.93% -67.44%
Income Tax -$3.634M -$2.410M $0.00
% Of Pretax Income
Net Earnings -$29.80M -$3.969M -$3.227M
YoY Change 172.79% -60.94% -67.44%
Net Earnings / Revenue -992.25% -7171.11%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.701M -$1.731M -$1.192M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.30M $13.40M $27.00M
YoY Change 603.73% -67.32% -45.89%
Cash & Equivalents $22.10M $13.37M $15.51M
Short-Term Investments $72.20M $6.400M
Other Short-Term Assets $2.500M $800.0K $1.300M
YoY Change 525.0% -38.46% -13.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $97.90M $14.60M $28.30M
YoY Change 570.55% -65.45% -44.94%
LONG-TERM ASSETS
Property, Plant & Equipment $900.0K $800.0K $100.0K
YoY Change 12.5% 253.98% -66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $0.00 $100.0K
YoY Change -100.0% -50.0%
Total Long-Term Assets $61.70M $14.30M $11.80M
YoY Change 331.47% 19.52% -1.67%
TOTAL ASSETS
Total Short-Term Assets $97.90M $14.60M $28.30M
Total Long-Term Assets $61.70M $14.30M $11.80M
Total Assets $159.6M $28.90M $40.10M
YoY Change 452.25% -46.7% -36.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.800M $500.0K $1.500M
YoY Change 460.0% -80.77% -48.28%
Accrued Expenses $3.000M $2.500M $7.800M
YoY Change 20.0% -69.33% -12.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $400.0K $11.60M
YoY Change -25.0% -96.36% 673.33%
Total Short-Term Liabilities $6.000M $4.866M $20.90M
YoY Change 71.43% -79.0% 54.59%
LONG-TERM LIABILITIES
Long-Term Debt $15.10M $4.000M $0.00
YoY Change 277.5%
Other Long-Term Liabilities $12.10M $11.20M $2.600M
YoY Change 8.04% 202.7% -80.0%
Total Long-Term Liabilities $27.20M $15.20M $2.600M
YoY Change 78.95% 310.81% -80.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.000M $4.866M $20.90M
Total Long-Term Liabilities $27.20M $15.20M $2.600M
Total Liabilities $40.30M $20.95M $26.90M
YoY Change 92.82% -30.93% -10.03%
SHAREHOLDERS EQUITY
Retained Earnings -$38.41M
YoY Change -86.03%
Common Stock $3.122M
YoY Change -98.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $119.3M -$35.88M $13.20M
YoY Change
Total Liabilities & Shareholders Equity $159.6M $28.93M $40.10M
YoY Change 452.25% -46.63% -36.79%

Cashflow Statement

Concept 2017 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$29.80M -$3.969M -$3.227M
YoY Change 172.79% -60.94% -67.44%
Depreciation, Depletion And Amortization $363.0K -$160.0K $86.00K
YoY Change 4.91% -500.0% 115.0%
Cash From Operating Activities -$28.23M -$31.09M -$2.860M
YoY Change -24.24% 252.89% -65.38%
INVESTING ACTIVITIES
Capital Expenditures $495.0K $0.00 $0.00
YoY Change 6087.5% -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$68.62M $15.21M $0.00
YoY Change -551.15% -6184.0% -100.0%
Cash From Investing Activities -$69.12M $15.21M $0.00
YoY Change -554.7% -5344.83% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.666M
YoY Change -91.65%
Debt Paid & Issued, Net $3.567M
YoY Change
Cash From Financing Activities 106.1M 2.540M 4.320M
YoY Change 1303.29% -5180.0% -70.85%
NET CHANGE
Cash From Operating Activities -28.23M -31.09M -2.860M
Cash From Investing Activities -69.12M 15.21M 0.000
Cash From Financing Activities 106.1M 2.540M 4.320M
Net Change In Cash 8.748M -13.34M 1.460M
YoY Change -160.29% 45.79% -86.72%
FREE CASH FLOW
Cash From Operating Activities -$28.23M -$31.09M -$2.860M
Capital Expenditures $495.0K $0.00 $0.00
Free Cash Flow -$28.73M -$31.09M -$2.860M
YoY Change -22.93% 254.91% -65.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38406000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28934000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-35875000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-591000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2966000
CY2017Q4 us-gaap Assets
Assets
159628000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2784000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-10923000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3117000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
579000
CY2017Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
103000
CY2017Q4 us-gaap Liabilities
Liabilities
40319000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
265000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
442000
CY2016Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
20000
CY2016Q4 us-gaap Liabilities
Liabilities
20948000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
72192000
CY2016Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
400000
CY2017Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
33626000
CY2016Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
10477000
CY2016 us-gaap Interest Expense
InterestExpense
452000
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-226000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3076000
CY2016Q4 svra Accrued Interest On Convertable Promissory Notes
AccruedInterestOnConvertablePromissoryNotes
151000
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3448000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
979000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
11948000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
9708000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
7181000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2305000
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
297000
CY2016Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
303000
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
43861000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
186522000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
958000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68203000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
119309000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159628000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
27000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30509522
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3162573
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30509522
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3162573
CY2016 us-gaap Revenues
Revenues
400000
CY2015 us-gaap Revenues
Revenues
54000
CY2017 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
18512000
CY2016 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8182000
CY2015 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4321000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11081000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2820000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1650000
CY2017 us-gaap Depreciation
Depreciation
363000
CY2016 us-gaap Depreciation
Depreciation
346000
CY2015 us-gaap Depreciation
Depreciation
6000
CY2016 us-gaap Operating Expenses
OperatingExpenses
11348000
CY2015 us-gaap Operating Expenses
OperatingExpenses
5977000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-5923000
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-218000
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
76000
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1816000
CY2017 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
-280000
CY2016 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
44000
CY2015 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
-265000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3475000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-332000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33431000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11280000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8999000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3634000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-357000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-29797000
CY2017 us-gaap Operating Expenses
OperatingExpenses
29956000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-29956000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-10948000
CY2017 us-gaap Interest Expense
InterestExpense
1161000
CY2015 us-gaap Interest Expense
InterestExpense
2585000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
209000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28248000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11514000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-8999000
CY2017 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
578000
CY2016 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
94000
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
183000
CY2017 svra Deemed Dividend On Beneficial Conversion Feature
DeemedDividendOnBeneficialConversionFeature
404000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30779000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11017000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9182000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1595000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-591000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-46000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8999000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.62
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.48
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17521119
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1960490
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
968810
CY2014Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
20271000
CY2015 svra Temporary Equity Issuance To Redemption Value Adjustment
TemporaryEquityIssuanceToRedemptionValueAdjustment
22531000
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
42985000
CY2016 svra Temporary Equity Issuance Of Convertible Preferred Stock
TemporaryEquityIssuanceOfConvertiblePreferredStock
782000
CY2017 svra Temporary Equity Value Conversion Of Stock
TemporaryEquityValueConversionOfStock
-44439000
CY2015 svra Accretion Of Redeemable Convertible Preferred Stock Deficit
AccretionOfRedeemableConvertiblePreferredStockDeficit
-183000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
153000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-27328000
CY2016 svra Accretion Of Redeemable Convertible Preferred Stock Deficit
AccretionOfRedeemableConvertiblePreferredStockDeficit
-94000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2016 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2851000
CY2017 svra Accretion Of Redeemable Convertible Preferred Stock Deficit
AccretionOfRedeemableConvertiblePreferredStockDeficit
-578000
CY2017 svra Issuance Of Common Stock Upon Exercise Of Warrants Amount
IssuanceOfCommonStockUponExerciseOfWarrantsAmount
384000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
10045000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
44438000
CY2017 svra Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
370000
CY2017 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
404000
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
35846000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
89598000
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
359000
CY2017 svra Issuance Of Common Stock Upon At The Market Sales Net
IssuanceOfCommonStockUponAtTheMarketSalesNet
1665000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2017 svra Adjustments To Additional Paid In Capital Issuance Of Call Option Derivative
AdjustmentsToAdditionalPaidInCapitalIssuanceOfCallOptionDerivative
344000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
552000
CY2017 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-280000
CY2016 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
228000
CY2015 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-265000
CY2017 svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
2240000
CY2016 svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
184000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
336000
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
199000
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
642000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-218000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-76000
CY2016 svra Accretion On Discount To Convertible Promissory Notes
AccretionOnDiscountToConvertiblePromissoryNotes
269000
CY2015 svra Accretion On Discount To Convertible Promissory Notes
AccretionOnDiscountToConvertiblePromissoryNotes
1948000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
401000
CY2017 svra Accretion On Discount To Short Term Investments
AccretionOnDiscountToShortTermInvestments
136000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
552000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
209000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
153000
CY2017 svra Issuance Of Call Option Derivative
IssuanceOfCallOptionDerivative
344000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2820000
CY2017 svra Increase Decrease In Grant And Award Receivable
IncreaseDecreaseInGrantAndAwardReceivable
-400000
CY2016 svra Increase Decrease In Grant And Award Receivable
IncreaseDecreaseInGrantAndAwardReceivable
400000
CY2015 svra Increase Decrease In Grant And Award Receivable
IncreaseDecreaseInGrantAndAwardReceivable
-961000
CY2017 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
454000
CY2016 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-393000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2110000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
289000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-214000
CY2017 svra Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-26000
CY2016 svra Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
14000
CY2015 svra Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
6000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
159000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1780000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-200000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28234000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8370000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4778000
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3442000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
495000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2017 svra Maturities Of Available For Sale Securities
MaturitiesOfAvailableForSaleSecurities
4800000
CY2017 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
76862000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-69115000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8000
CY2017 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
14894000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3569000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4415000
CY2017 svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
384000
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
89598000
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3567000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1666000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2016 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
782000
CY2015 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
8773000
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
460000
CY2016 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
81000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
106089000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5117000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8773000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
8000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-49000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8748000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3310000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3995000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16683000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12688000
CY2016 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
12375000
CY2015 svra Noncash Equipment Under Capital Lease
NoncashEquipmentUnderCapitalLease
-1102000
CY2016 svra Non Cash Contingent Liability
NonCashContingentLiability
9524000
CY2017 svra Non Cash Extinguishment And Derecognition Of Put Options
NonCashExtinguishmentAndDerecognitionOfPutOptions
2202000
CY2015 svra Non Cash Extinguishment And Derecognition Of Put Options
NonCashExtinguishmentAndDerecognitionOfPutOptions
2708000
CY2017 svra Shares Issued In Connection Of Business Combination And Assumed Equity Awards
SharesIssuedInConnectionOfBusinessCombinationAndAssumedEquityAwards
35846000
CY2016 svra Shares Issued In Connection Of Business Combination And Assumed Equity Awards
SharesIssuedInConnectionOfBusinessCombinationAndAssumedEquityAwards
2851000
CY2017 svra Non Cash Beneficial Conversion Feature
NonCashBeneficialConversionFeature
404000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
2000
CY2016Q4 svra Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
243000
CY2017Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
196000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Use of Estimates </font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management&#8217;s estimates include those related to the accrual of research and development costs, the valuation of preferred and common shares, certain financial instruments recorded at fair value, stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates. </font></p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Concentration of Credit Risk </font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and foreign exchange derivatives not designated as hedging. The Company places its cash and cash equivalents with a limited number of high quality financial institutions and at times may exceed the amount of insurance provided on such deposits. </font></p></div>
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2017 svra Liquid Investments Maturity Period
LiquidInvestmentsMaturityPeriod
three months or less
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2017 us-gaap Revenues
Revenues
0
CY2017 svra Percentage Of Present Value Of Minimum Lease Payments Exceeding Fair Value Of Equipment Determined Lease As Capital Lease
PercentageOfPresentValueOfMinimumLeasePaymentsExceedingFairValueOfEquipmentDeterminedLeaseAsCapitalLease
0.90
CY2017 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
10930000
CY2017Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
834000
CY2016Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
357000
CY2017Q4 svra Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
2129000
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1776000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1297000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
851000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
504000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5625000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7500000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2775000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15900000
CY2017Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
749000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
376000
CY2017Q4 us-gaap Line Of Credit
LineOfCredit
14775000
CY2016 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.0043
CY2017Q2 svra Minimum Market Cap Upon Completion Of Merger
MinimumMarketCapUponCompletionOfMerger
100000000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9034210
CY2017Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
23550
CY2017Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
900000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2017Q4 svra Principal Payments Of Debt And End Of Term Charge Non Current
PrincipalPaymentsOfDebtAndEndOfTermChargeNonCurrent
15151000
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
83000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
293000
CY2016Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
111000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
158000
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
35000
CY2017Q4 svra Forward Currency Exchange Derivative Current
ForwardCurrencyExchangeDerivativeCurrent
40000
CY2017Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
194000
CY2016Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
94000
CY2017Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1308000
CY2016Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1855000
CY2017Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
323000
CY2016Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
458000
CY2017Q4 svra Accrued Compensation
AccruedCompensation
1328000
CY2016Q4 svra Accrued Compensation
AccruedCompensation
117000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
47000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
72238000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
46000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
72192000
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016 us-gaap Fair Value Inputs Probability Of Default
FairValueInputsProbabilityOfDefault
0.850
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2600000
CY2017Q4 svra Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
501000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4072391
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14158371
CY2016Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
11927875
CY2016Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11927875
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2016Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15799906
CY2016Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
43861
CY2016Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
44439
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2068684
CY2017Q1 svra Operating Lease Office Space
OperatingLeaseOfficeSpace
13707
CY2017Q1 svra Lease Commencement Date
LeaseCommencementDate
2017-07-01
CY2014Q2 svra Lease Commencement Date
LeaseCommencementDate
2014-06-01
CY2017Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-31
CY2014Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2019-11-30
CY2017Q1 svra Lease Agreement Date
LeaseAgreementDate
2014-06-19
CY2017Q1 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
44000
CY2014Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
5000
CY2017Q1 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.030
CY2017Q4 svra Lease Commencement Date
LeaseCommencementDate
2018-01-01
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2017Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
13000
CY2017Q4 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.02
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
822000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
831000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
396000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
97000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2146000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
292000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
301000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
593000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
31000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
562000
CY2017Q2 svra Potential Amount Of Future Obligation
PotentialAmountOfFutureObligation
500000
CY2017 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
500000
CY2017 svra Employment Agreement Description
EmploymentAgreementDescription
Upon termination without cause, and not as a result of death or disability, each of such officers is entitled to receive a payment of base salary for three to twelve months following termination of employment and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for three to twelve months or until such officer is covered under a separate plan from another employer. Upon a termination other than for cause or for good reason within twelve months following a change in control, each of such officers will be entitled to the same benefits as upon termination without cause and will also be entitled to certain acceleration of such officer's outstanding unvested options at the time of such termination
CY2017 svra Purchase Price Of Common Stock Covered By Stock Option As Percentage Of Fair Market Value Of Common Stock
PurchasePriceOfCommonStockCoveredByStockOptionAsPercentageOfFairMarketValueOfCommonStock
Less than 100%
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1916832
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
863001
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
552000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
209000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21942000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8502000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8999000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-11489000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2778000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2820000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-814000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-357000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-814000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-357000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11367000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3835000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3059000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1487000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4009000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3488000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3427000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2435000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1983000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1691000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1126000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22850000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14931000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
7181000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2305000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 svra Effective Income Tax Rate Orphan Drug Credit In Qualifying Expenditures
EffectiveIncomeTaxRateOrphanDrugCreditInQualifyingExpenditures
0.50
CY2017 svra Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
-2800000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15190000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15669000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12626000
CY2017Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
345000
CY2016Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
455000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23315000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
674000
CY2015 svra Income Tax Reconciliation Tax Credit State Research Credits Generated Net Of Federal Benefit
IncomeTaxReconciliationTaxCreditStateResearchCreditsGeneratedNetOfFederalBenefit
175000
CY2017 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
762000
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1363000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
333000
CY2017 svra Income Tax Reconciliation Note Conversion
IncomeTaxReconciliationNoteConversion
618000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
4096000
CY2017 svra Income Tax Reconciliation Transaction Costs
IncomeTaxReconciliationTransactionCosts
657000
CY2015 svra Income Tax Reconciliation Interest On Convertible Debt
IncomeTaxReconciliationInterestOnConvertibleDebt
867000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
486000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
445000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
188000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7900000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4000000
CY2016Q4 svra Deferred Tax Liabilities Stock Based Compensation
DeferredTaxLiabilitiesStockBasedCompensation
2000
CY2017Q4 svra Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
87000
CY2016Q4 svra Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
257000
CY2017Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
378000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
7181000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2305000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7646000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2564000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13194000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7483000
CY2017Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
6000
CY2016Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
11000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9770000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
7241000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
9500000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
400000
CY2017Q4 svra Percentage Increase In Shareholders Ownership Interest
PercentageIncreaseInShareholdersOwnershipInterest
0.05
CY2017Q4 svra Minimum Percentage Points Change In Ownership Interest
MinimumPercentagePointsChangeInOwnershipInterest
0.0050
CY2017 svra Change In Ownership Interest Period
ChangeInOwnershipInterestPeriod
P3Y
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2016 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4088581
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9836264
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8218039
CY2017 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-30779000
CY2016 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-11017000
CY2015 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-9182000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4774000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9343000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6543000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-9296000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4974000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-11504000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-6817000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6502000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2016Q4 us-gaap Revenues
Revenues
400000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1691000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1983000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3230000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4044000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1676000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-2051000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3227000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-3969000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.97
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.21
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31

Files In Submission

Name View Source Status
0001564590-18-005610-index-headers.html Edgar Link pending
0001564590-18-005610-index.html Edgar Link pending
0001564590-18-005610.txt Edgar Link pending
0001564590-18-005610-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201803141834313558583.jpg Edgar Link pending
g201803141834313868584.jpg Edgar Link pending
g201803141834370308585.jpg Edgar Link pending
g201803141834385448586.jpg Edgar Link pending
g201803141834387178587.jpg Edgar Link pending
g201803141834387328588.jpg Edgar Link pending
g201803141834387538589.jpg Edgar Link pending
g201803141834488528590.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-10k_20171231.htm Edgar Link pending
svra-20171231.xml Edgar Link completed
svra-20171231.xsd Edgar Link pending
svra-20171231_cal.xml Edgar Link unprocessable
svra-20171231_def.xml Edgar Link unprocessable
svra-20171231_lab.xml Edgar Link unprocessable
svra-20171231_pre.xml Edgar Link unprocessable
svra-ex108_127.htm Edgar Link pending
svra-ex109_128.htm Edgar Link pending
svra-ex211_157.htm Edgar Link pending
svra-ex231_707.htm Edgar Link pending
svra-ex311_11.htm Edgar Link pending
svra-ex312_10.htm Edgar Link pending
svra-ex321_9.htm Edgar Link pending
svra-ex41_129.htm Edgar Link pending